SPY338.34-7.44 -2.15%
DIA276.14-7.20 -2.54%
IXIC11,334.81-213.47 -1.85%

Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $270

Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $241 to $270.

· 10/13/2020 08:26
Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $241 to $270.